Pamiparib (BGB-290; Partruvix) is positioned as an oral, brain-penetrant PARP1/2 inhibitor that blocks PARylation and traps PARP–DNA complexes to promote synthetic lethality in homologous recombination-deficient tumors. Beyond preclinical rationale emphasizing intracranial activity, regulators in China granted conditional approval in 2021 for germline BRCA-mutated recurrent ovarian-related cancers. The drug profile continues to matter to neuro-oncology stakeholders because intracranial penetration is often the limiting factor for PARP inhibitor utility in brain-relevant disease settings. The summary reinforces how mechanistic design and demonstrated brain distribution feed regulatory decisions.